Entering text into the input field will update the search result below

Exelixis drops quickly on day four of Cabometyx patent trial (update)

May 19, 2022 1:08 PM ETExelixis, Inc. (EXEL)By: Joshua Fineman, SA News Editor8 Comments

Update 1:08pm Updates shares, adds Suntrust analyst comment.

Exelixis (NASDAQ:EXEL) plunged 11% during day four of the Cabometyx patent trial.

The judge in the case appeared to telegraph that he will find that the 776 patent, which goes to October 2030, won't be

Recommended For You

Comments (8)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

whitehead1 profile picture
chatter on message board that this company may get bid soon, any truth to this?
I guess best thing can happen is EXEL gets bought and find a better management who can do something
Philipp Stuelcken profile picture
It remains to be the best strategy to buy this stock between 15-17 and sell it between 21-23...
@Philipp Stuelcken Agree . I did that twice. Will see if it works further :)
Philipp Stuelcken profile picture
@valtr Yeah me too :)
Judges don't telegraph results. They do comment favorably for both sides sometimes, this is a form of "dynamite charge" to motivate settlement.
I bought this company hold it for 1 year and sold for the exact same price. Such a dissapointing management.
Why don’t use that nearly 2 Billions to do something with the dropping share price !!!
@RCI23 In all honesty...MMM is sitting on a full house now, literally watching the whole markets collapse and they have cash. Lots of it on hand. Well done..

About EXEL

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Exelixis, Inc.
Natera, Inc.
Apellis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Karuna Therapeutics, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.